Cardiology
FDA/CDC
New Vascepa indication opens up treatment to millions; “Most significant event since statins”
Conference Coverage
Why STEMI patients benefit from PCI of nonculprit lesions
“This immediately explains the clinical benefit observed with preventive PCI in STEMI patients with multivessel disease.” – Dr. Frans Van de Werf...
Conference Coverage
Cardiac biomarkers refine antihypertensive drug initiation decisions
PHILADELPHIA – Analysis showcases a better way to select patients for intensive BP lowering.
News
Adult survivors of childhood cancer are experiencing fewer major cardiac events
Reduced radiation exposure is a likely contributor to the improved cardiovascular outcomes.
News
Cardiovascular risks associated with cannabis use
Review authors suggest cardiovascular patients may benefit from cannabis screening and testing.
FDA/CDC
FDA approves CV disease benefit for once-weekly semaglutide
The approval was based on data from the SUSTAIN 6 in patients with type 2 diabetes and established heart disease.
Conference Coverage
Are providers asking about menstrual bleeding before/during anticoagulant therapy?
Conference Coverage
SPRINT-type BP control provides up to 3 years of additional life
PHILADELPHIA – Survival advantage of intensive over standard blood pressure lowering is age dependent.
Conference Coverage
Pharmacist BP telemonitoring cut cardiovascular events, turned profit
PHILADELPHIA – Was the 51% reduction in major cardiovascular events a fluke?
News
HRS urges consumers to direct questions about wearables’ data to clinicians